The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain
Value Health
.
2014 Nov;17(7):A350.
doi: 10.1016/j.jval.2014.08.727.
Epub 2014 Oct 26.
Authors
J Sánchez-Covisa
1
,
M Capel
1
,
R Schmidt
2
,
M Charokopou
2
,
B G Verheggen
2
Affiliations
1
AstraZeneca, Madrid, Spain.
2
Pharmerit International, Rotterdam, The Netherlands.
PMID:
27200677
DOI:
10.1016/j.jval.2014.08.727
No abstract available